Omeros Corporation OMER
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +3.78%
- 1 year
- +143.25%
- Open
- 18.66
- Prev close
- 18.44
- Mkt cap
- 1.29B
- Vol
- 890.56K
- Avg vol
- 1.67M
- EPS
- 1.22
- P/E
- 14.61
- Div yield
- 0.00%
More statistics
- Low
- 17.62
- High
- 18.76
- Forward P/E
- 14.50
- Beta
- 2.99
- Short ratio
- 8.63
- Inst. own
- 51.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 18.52
- 200-d avg
- 13.49
- 1y target
- 27.50
30m chart
Built from the cached five-day intraday bars.
Signals (13)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 2:55 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 10:55 AM | 5 hours ago |
| SMA: Bearish | Nov 2, 10:55 AM | 5 hours ago |
| SMA: Bullish | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 4 days ago |
| RSI: Overbought | Oct 29, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 5 days ago |
Key statistics
- Market cap
- 1.29B
- Enterprise value
- 1.50B
- Trailing P/E
- 14.61
- Forward P/E
- 14.50
- PEG ratio
- 0.81
- Price / sales
- 33.59
- Price / book
- 0.00
- EPS (TTM)
- 1.22
- Beta
- 2.99
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 324.88%
- Revenue (TTM)
- 38.42M
- Revenue growth
- 0.00%
- Free cash flow
- 183.31M
- Total cash
- 131.95M
- Total debt
- 296.87M
- Return on equity
- 0.00%
- Shares outstanding
- 72.39M
- Short % of float
- 16.37%
- 50-day average
- 18.52
- 200-day average
- 13.49
Analyst view
Consensus: none
- Target (low)
- 22.00
- Target (mean)
- 27.50
- Target (high)
- 33.00
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | 0.02 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.2683 | 0.15 | +0.42 | +155.91% |
| May 13, 2026 | Mar 31, 2026 | -0.40 | -0.24 | +0.16 | +40.00% |
| Mar 31, 2026 | Dec 31, 2025 | -0.55 | 3.14 | +3.69 | +670.91% |
| Nov 13, 2025 | Sep 30, 2025 | -0.58 | -0.47 | +0.11 | +18.97% |
| Aug 14, 2025 | Jun 30, 2025 | -0.55 | -0.43 | +0.12 | +21.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 22, 2026 | Cantor Fitzgerald | up | Neutral | Overweight |
| Jun 26, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 10, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 21, 2026 | D. Boral Capital | main | Buy | Buy |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- omeros.com
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- Omeros (NASDAQ:OMER) Shares Gap Down – Here’s Why
- Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
- Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
- Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
- Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
Your note
Sign in to keep a note on OMER — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORGES DAVID J. | Officer | Sale | Sep 22, 2026 | 0 |
| CABLE THOMAS J | Director | Sale | Aug 19, 2026 | 35,067 |
| CANCELMO PETER B. | General Counsel | Sale | Aug 30, 2026 | 200 |
| DEMOPULOS GREGORY A. M.D. | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 2,193,250 |
| HANISH ARNOLD C | Director | Sale | Aug 26, 2026 | 12,400 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.35% | 6,044,633 | 107.78M | Jun 29, 2026 |
| Ingalls & Snyder LLC | 5.06% | 3,659,523 | 65.25M | Jun 29, 2026 |
| UBS Group AG | 4.35% | 3,148,384 | 56.14M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.24% | 3,072,050 | 54.77M | Jun 29, 2026 |
| State Street Corporation | 3.20% | 2,319,906 | 41.36M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.64% | 1,914,460 | 34.13M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 2,172,336 | 38.73M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.58% | 1,867,153 | 33.29M | Sep 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco Biotechnology & Genome ETF | 1.28% | 929,585 | 16.57M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 831,218 | 14.82M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.09% | 788,562 | 14.06M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 0.74% | 533,750 | 9.52M | Sep 29, 2026 |